Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.
1. A method of making a composition comprising microparticles comprising DAS181, the method comprising:
a) providing a feedstock composition that is 8-12% (wt/wt) histidine, and further comprising DAS181, a counterion and an organic solvent; and
b) cooling the composition to below 25° C., whereby a composition comprising microparticles comprising DAS181 is formed.
2. The method of claim 1 , wherein the counterion is sodium sulfate.
3. The method of claim 1 wherein the counterion is magnesium sulfate.
4. The method of claim 1 wherein the feedstock composition is 70-80% (wt/wt) DAS181.
5. The method of claim 1 wherein the feedstock composition is 8-12% (wt/wt) trehalose.
6. The method of claim 1 wherein the feedstock composition is 20-30% (wt/wt) isopropanol.
7. The method of claim 1 wherein the resulting microparticles are 60% to 75% (wt/wt) a polypeptide consisting of SEQ ID NO:1 or SEQ ID NO:2, when anhydrous.
8. The method of claim 1 , wherein the feedstock composition further comprises a scavenging agent.
9. A composition comprising microparticles, wherein the microparticles are about 60-70% wt/wt DAS181, 7-15% wt/wt histidine, 7-11% wt/wt trehalose, 4-8% wt/wt magnesium sulfate, and 8-12% wt/wt water.
10. The composition of claim 9 wherein the microparticles are 62%-68% (wt/wt) a polypeptide comprising SEQ ID NO:1 or a polypeptide comprising SEQ ID NO:2.
11. The composition of claim 9 wherein the microparticles have a Mass Median Aerodynamic Diameter (MMAD) of 1-8 microns, 2-8 microns or 3-8 microns.
12. The composition of claim 11 wherein the microparticles have a Geometric Standard Deviation (GSD) of 1.5-1.7, 1.3-1.6, or 1.4-1.6.
13. The composition of claim 9 wherein the weight percent of microparticles having a fine particle fractionation (FPF) below 5 microns is less than 10%.
14. A composition comprising microparticles, wherein the microparticles are about 69-74% wt/wt DAS181, 9-17% wt/wt histidine, 8-12% wt/wt trehalose, and 4-8% wt/wt magnesium sulfate.
15. The composition of claim 14 wherein the microparticles have a GSD of 1.5-1.7, 1.3-1.6, or 1.4-1.6.
16. The composition of claim 14 wherein the weight percent of microparticles having a FPF below 5 microns is less than 10%.
17. A composition comprising microparticles, wherein the microparticles are about 80-90% wt/wt DAS181, 1.5-3.5% wt/wt sodium sulfate, and 8-12% water.
18. The composition of claim 17 wherein the microparticles have a GSD of 1.2-1.8, 1.3-1.7 or 1.4-1.6.
19. The composition of claim 17 wherein the weight percent of microparticles having a fine particle fractionation (FPF) below 5 microns is less than 10%.
20. The composition of claim 9 comprising 3-6% wt/wt histidine free base and 5-9% wt/wt histidine hydrochloride.
21. The composition of claim 14 comprising 3-8% wt/wt histidine free base and 5-9% wt/wt histidine hydrochloride.
22. A composition comprising microparticles, wherein the microparticles are about 60-70% wt/wt DAS181, 8-15% wt/wt histidine, 7-11% wt/wt trehalose, 4-8% wt/wt magnesium sulfate, and 8-12% water.
23. A composition comprising microparticles, wherein the microparticles are about 69-74% wt/wt DAS181, 7-17% wt/wt histidine, 8-12% wt/wt trehalose, and 4-8% wt/wt magnesium sulfate.